12 assets in Small Intestine Adenocarcinoma

Therapeutic assets addressing Small Intestine Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Adenovirus 5/F35-Human Guanylyl Cyclase C-Padre Small Intestine Adenocarcinoma	Thomas Jefferson University	P2	CCC (53)
Dostarlimab Small Intestine Adenocarcinoma	UNICANCER	P2	CCC (53)
Human Adenovirus C Serotype 5 Small Intestine Adenocarcinoma	Thomas Jefferson University	P2	CCC (53)
Ipilimumab Small Intestine Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Neomycin Small Intestine Adenocarcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Nivolumab Small Intestine Adenocarcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Pembrolizumab Small Intestine Adenocarcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Vancomycin Small Intestine Adenocarcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Vandazole Small Intestine Adenocarcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
ad5.f35-hgucy2c-padre vaccine Small Intestine Adenocarcinoma	Thomas Jefferson University	P1	CC (43)
Lm-Gucy2C Vaccine Small Intestine Adenocarcinoma	Thomas Jefferson University	P1	CC (43)
Ropidoxuridine Small Intestine Adenocarcinoma	National Cancer Institute (NCI)	P1	CC (41)